Pfizer raises 2026 outlook to $62B-$64B revenue and $2.95-$3.05 adjusted EPS, targeting high single-digit revenue CAGR from 2028-2033

• "I'm pleased with another strong quarter for Pfizer." (Chairman & CEO Albert Bourla) "Our excellent commercial execution, including 32% operational revenue growth in the quarter for our launch and acquired products shows the underlying strength of our

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.